Market Research Logo

Cancer Tissue Diagnostics Market: North America to Retain Its Dominance Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016 - 2026

Cancer Tissue Diagnostics Market: North America to Retain Its Dominance Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016 - 2026

The global cancer tissue diagnostics market is poised to grow from close to US$ 4,350 Mn in 2016 to nearly US$ 9,650 Mn by 2026 end. This represents a CAGR of 8.3% over the forecast period. The global market for cancer tissue diagnostics represents incremental opportunity of about US$ 5,300 Mn between 2016 and 2026.

Global Cancer Tissue Diagnostics Market Attractiveness Analysis by Region, 2016 – 2026

North America dominated the global cancer tissue diagnostics market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America accounted for 36.5% value share in 2016 and is projected to account for more than 40% share by 2026 end. In terms of value, APEJ is expected to register a CAGR of 8.0% during the forecast period. Despite a low value CAGR of 5.7%, the MEA cancer tissue diagnostics market is projected to grow 1.9X over 2016–2026.

Constantly growing list of cancer biomarkers boosting the cancer tissue diagnostics market

Sheer number of biomarkers that can be utilised for early cancer detection from blood or plasma samples are constantly increasing, which is expected to bring new cancer biomarker tests in the market in the near future. For instance, researchers at the University of Sheffield have recently identified over 700 new blood biomarkers that can be used for early cancer detection. As per OECD statistics, the global biomarkers market for companion diagnostics was valued at about US$ 8.4 Bn in 2016. The growth in companion diagnostics is indicative of acceptance of biomarkers in healthcare systems and may offer attractive incentives for biomarkers business development.

Advanced diagnostics at reduced costs aiding the global cancer tissue diagnostics market

After the completion of the human genome project in 2003, cost of assembling one genome has reduced tremendously and also cut down the time of analysis with development of highly advanced sequencing equipment. For instance, in January 2014, Illumina Inc. launched HighSeq X Ten Sequencer, which cut down the cost of genome sequencing to as low as US$ 1,000 including reagents cost and sample preparation equipment depreciation cost. Further advancements may continue to push down the cost for less than the cost of an X-ray, which would enhance the accessibility of this technology and thus drive the growth of the market. This also facilitates the use of highly advanced technologies by smaller research and clinical laboratories that possess less technical expertise and low resources.

Enormous R&D investment poses a threat to the expansion of the cancer tissue diagnostics market

Development of all high end instruments such as PET, MRI, SPECT equipment as well as next-generation sequencing platforms, analytical instruments used for laboratory analysis of cancer specimen etc. need huge investments of time and money, which is expected to be the prime factor impacting the cancer tissue diagnostics market. Also, all big pharmaceutical companies are entering into the diagnostics business and are thus cutting down the growth prospects of diagnostic giants such as Roche, Danaher etc. If at all a company develops innovative diagnostic testing, they still have to invest in expensive clinical utility studies, and there is no guarantee that the product will get coverage.

Meeting the needs of hospital laboratories presents a significant opportunity for the growth of the global cancer tissue diagnostics market

Due to healthcare cost containment in majority of mature markets, hospital based laboratories are facing pressure to supply more services at reduced costs. Healthcare facilities are facing increased aging population and rising prevalence of chronic diseases. By 2018, almost 10% of the global population will be 65 and above. Also global healthcare spending is expected to witness 5.2% growth every year till 2018. This imposes cost management pressure on diagnostic labs. Thus, several laboratories have started adapting informatics solutions, which helps them to increase overall productivity with existing resources. In line with this, manufacturers of diagnostic tests can grab the opportunity to provide complementary services and support. For instance, Abbott laboratories recently launched AlinIQ support and services to help their laboratory partners manage operations to maximise throughput and capacity.


1. Executive Summary
2. Cancer Tissue Diagnostics Introduction
2.1. Cancer Tissue Diagnostics Definition
2.2. Cancer Tissue Diagnostics Taxonomy
3. Cancer Tissue Diagnostics Analysis Scenario
3.1. Cancer Tissue Diagnostics Size (US$ Mn) and Forecast
3.1.1. Market Size and Y-o-Y Growth
3.1.2. Absolute $ Opportunity
4. Cancer Tissue Diagnostics Analysis Scenario
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Trends
4.6. Cancer Epidemiology
4.7. Cancer Tissue Diagnostics Regulatory and Reimbursement Scenario
4.8. Porter’s Analysis
5. Global Cancer Tissue Diagnostics Analysis and Forecast, By Test Type
5.1. Introduction
5.1.1. Basis Point Share (BPS) Analysis By Test Type
5.1.2. Y-o-Y Growth Projections By Test Type
5.2. Market Size (US$ Mn) Forecast By Test Type
5.2.1. Immunohistochemical (IHC) Test
5.2.1.1. Breast Cancer
5.2.1.2. Stomach (gastric) Cancer
5.2.1.3. Colorectal Cancer
5.2.1.4. Prostate Cancer
5.2.1.5. Others
5.2.2. In situ hybridization (ISH) Test
5.2.2.1. Breast Cancer
5.2.2.2. Non-Small Cell Lung Cancer (NSCLC)
5.2.2.3. Bladder Cancer
5.2.2.4. Others
5.3. Market Attractiveness Analysis By Test Type
6. Global Cancer Tissue Diagnostics Analysis and Forecast, By Region
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis By Region
6.1.2. Y-o-Y Growth Projections By Region
6.2. Market Size (US$ Mn) Forecast By Region
6.2.1. North America
6.2.2. Western Europe
6.2.3. Asia Pacific Excl. Japan (APEJ)
6.2.4. Japan
6.2.5. Latin America
6.2.6. Eastern Europe
6.2.7. Middle East and Africa (MEA)
6.3. Market Attractiveness Analysis By Region
7. North America Cancer Tissue Diagnostics Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis
7.1.2. Y-o-Y Growth Projections
7.2. Market Size (US$ Mn) Forecast By Test Type
7.2.1. Immunohistochemical (IHC) Test
7.2.1.1. Breast Cancer
7.2.1.2. Stomach (gastric) Cancer
7.2.1.3. Colorectal Cancer
7.2.1.4. Prostate Cancer
7.2.1.5. Others
7.2.2. In situ hybridization (ISH) Test
7.2.2.1. Breast Cancer
7.2.2.2. Non-Small Cell Lung Cancer (NSCLC)
7.2.2.3. Bladder Cancer
7.2.2.4. Others
7.3. Market Value Forecast By Country, 2016–2026
7.3.1. United States
7.3.2. Canada
7.4. Market Attractiveness Analysis
7.4.1. By Test Type
7.4.2. By Country
8. Latin America Cancer Tissue Diagnostics Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis
8.1.2. Y-o-Y Growth Projections
8.2. Market Size (US$ Mn) Forecast By Test Type
8.2.1. Immunohistochemical (IHC) Test
8.2.1.1. Breast Cancer
8.2.1.2. Stomach (gastric) Cancer
8.2.1.3. Colorectal Cancer
8.2.1.4. Prostate Cancer
8.2.1.5. Others
8.2.2. In situ hybridization (ISH) Test
8.2.2.1. Breast Cancer
8.2.2.2. Non-Small Cell Lung Cancer (NSCLC)
8.2.2.3. Bladder Cancer
8.2.2.4. Others
8.3. Market Value Forecast By Country, 2016–2026
8.3.1. Brazil
8.3.2. Mexico
8.3.3. Rest of Latin America
8.4. Market Attractiveness Analysis
8.4.1. By Test Type
8.4.2. By Country
9. Western Europe Cancer Tissue Diagnostics Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis
9.1.2. Y-o-Y Growth Projections
9.2. Market Size (US$ Mn) Forecast By Test Type
9.2.1. Immunohistochemical (IHC) Test
9.2.1.1. Breast Cancer
9.2.1.2. Stomach (gastric) Cancer
9.2.1.3. Colorectal Cancer
9.2.1.4. Prostate Cancer
9.2.1.5. Others
9.2.2. In situ hybridization (ISH) Test
9.2.2.1. Breast Cancer
9.2.2.2. Non-Small Cell Lung Cancer (NSCLC)
9.2.2.3. Bladder Cancer
9.2.2.4. Others
9.3. Market Value Forecast By Country, 2016–2026
9.3.1. UK
9.3.2. France
9.3.3. Germany
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Western Europe
9.4. Market Attractiveness Analysis
9.4.1. By Test Type
9.4.2. By Country
10. Eastern Europe Cancer Tissue Diagnostics Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis
10.1.2. Y-o-Y Growth Projections
10.2. Market Size (US$ Mn) Forecast By Test Type
10.2.1. Immunohistochemical (IHC) Test
10.2.1.1. Breast Cancer
10.2.1.2. Stomach (gastric) Cancer
10.2.1.3. Colorectal Cancer
10.2.1.4. Prostate Cancer
10.2.1.5. Others
10.2.2. In situ hybridization (ISH) Test
10.2.2.1. Breast Cancer
10.2.2.2. Non-Small Cell Lung Cancer (NSCLC)
10.2.2.3. Bladder Cancer
10.2.2.4. Others
10.3. Market Value Forecast By Country, 2016–2026
10.3.1. Russia
10.3.2. Poland
10.3.3. Rest of Eastern Europe
10.4. Market Attractiveness Analysis
10.4.1. By Test Type
10.4.2. By Country
11. Asia Pacific Excl. Japan (APEJ) Cancer Tissue Diagnostics Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis
11.1.2. Y-o-Y Growth Projections
11.2. Market Size (US$ Mn) Forecast By Test Type
11.2.1. Immunohistochemical (IHC) Test
11.2.1.1. Breast Cancer
11.2.1.2. Stomach (gastric) Cancer
11.2.1.3. Colorectal Cancer
11.2.1.4. Prostate Cancer
11.2.1.5. Others
11.2.2. In situ hybridization (ISH) Test
11.2.2.1. Breast Cancer
11.2.2.2. Non-Small Cell Lung Cancer (NSCLC)
11.2.2.3. Bladder Cancer
11.2.2.4. Others
11.3. Market Value Forecast By Country, 2016–2026
11.3.1. China
11.3.2. Australia
11.3.3. India
11.3.4. ASEAN
11.3.5. Rest of APEJ
11.4. Market Attractiveness Analysis
11.4.1. By Test Type
11.4.2. By Country
12. Japan Cancer Tissue Diagnostics Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis
12.1.2. Y-o-Y Growth Projections
12.2. Market Size (US$ Mn) Forecast By Test Type
12.2.1. Immunohistochemical (IHC) Test
12.2.1.1. Breast Cancer
12.2.1.2. Stomach (gastric) Cancer
12.2.1.3. Colorectal Cancer
12.2.1.4. Prostate Cancer
12.2.1.5. Others
12.2.2. In situ hybridization (ISH) Test
12.2.2.1. Breast Cancer
12.2.2.2. Non-Small Cell Lung Cancer (NSCLC)
12.2.2.3. Bladder Cancer
12.2.2.4. Others
12.3. Market Attractiveness Analysis
12.3.1. By Test Type
13. MEA Cancer Tissue Diagnostics Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis
13.1.2. Y-o-Y Growth Projections
13.2. Market Size (US$ Mn) Forecast By Test Type
13.2.1. Immunohistochemical (IHC) Test
13.2.1.1. Breast Cancer
13.2.1.2. Stomach (gastric) Cancer
13.2.1.3. Colorectal Cancer
13.2.1.4. Prostate Cancer
13.2.1.5. Others
13.2.2. In situ hybridization (ISH) Test
13.2.2.1. Breast Cancer
13.2.2.2. Non-Small Cell Lung Cancer (NSCLC)
13.2.2.3. Bladder Cancer
13.2.2.4. Others
13.3. Market Value Forecast By Country, 2016–2026
13.3.1. GCC Countries
13.3.2. South Africa
13.3.3. Rest of MEA
13.4. Market Attractiveness Analysis
13.4.1. By Test Type
13.4.2. By Country
14. Competition Landscape
14.1. Competition Dashboard
14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
14.2.1. Abbott Laboratories
14.2.2. F. Hoffmann-La Roche Ltd.
14.2.3. Thermo Fisher Scientific Inc.
14.2.4. Ventana Medical Systems, Inc
14.2.5. Bio Rad Laboratories Inc.
14.2.6. Enzo Life Sciences, Inc.
14.2.7. Abcam plc.
14.2.8. BioGenex
14.2.9. Cell Signaling Technology, Inc.
14.2.10. Agilent Technologies, Inc.
14.2.11. PerkinElmer Inc.
14.2.12. Bio SB
14.2.13. Cancer Genetics Inc.
14.2.14. Danaher Corporation
14.2.15. ROSETTA GENOMICS
14.2.16. Nanoprobes, Inc.,
14.2.17. Creative-Biolabs
14.2.18. Enzo Life Sciences, Inc
14.2.19.Sigma-Aldrich Co. LLC
15. Assumptions and Acronyms Used
16.Research Methodology
List of Tables
Table 1: Global Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026
Table 2: Global Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Region, 2015 – 2026
Table 3: North America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 4: North America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026
Table 5: Latin America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 6: Latin America Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026
Table 7: Western Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 8: Western Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026
The market is expected to sTable revenue growth over the forecast period fuelled by demand for breast & lung cancer detection
Table 9: Eastern Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 10: Eastern Europe Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026
Table 11: APEJ Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 12: APEJ Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026
Regional market revenue growth for both tests is expected to remain sTable over the forecast period, given rising demand
Table 13: Japan Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026
Table 14: MEA Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 15: MEA Cancer Tissue Diagnostics Market Value (US$ Mn) Analysis and Forecast By Test Type, 2015 – 2026
List of Figures
Figure 1 : Global Cancer Tissue Diagnostics Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026
Figure 2 : Global Cancer Tissue Diagnostics Market Absolute $ Opportunity, 2016–2026
Figure 3: Global Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026
Figure 4: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026
Figure 5: Global Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026
Figure 6: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026
Figure 7: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026
Figure 8: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026
Figure 9: Global Cancer Tissue Diagnostics Market Share Analysis (%) By Region, 2016 & 2026
Figure 10: Global Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Region, 2015–2026
Figure 11: North America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 12: Latin America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 13: Western Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 14: Eastern Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 15: APEJ Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 16: Japan Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 17: MEA Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 18: Global Cancer Tissue Diagnostics Market Attractiveness Analysis By Region, 2016–2026
Figure 19: North America Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016, 2026
Figure 20: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 21: North America Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026
Figure 22: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026
Figure 23: North America Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026
Figure 24: North America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026
Figure 25: U.S. Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 26: Canada Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 27: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By Country, 2016 – 2026
Figure 28: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026
Figure 29: North America Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026
Figure 30: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026
Figure 31: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 32: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026
Figure 33: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026
Figure 34: Latin America Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026
Figure 35: Latin America Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026
Figure 36: Brazil Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 37: Mexico Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 38: Rest of Latin America Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 39: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026
Figure 40: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026
Figure 41: Latin America Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026
Figure 42: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026
Figure 43: Western Europe Cancer Tissue Diagnostics Market
Figure 44: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026
Figure 45: Western Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026
Figure 46: Western Europe Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026
Figure 47: Western Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026
Figure 48: Germany Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 49: Italy Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 50: France Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 51: U.K. Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 52: Spain Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 53: Rest Of Western Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 54: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026
Figure 55: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026
Figure 56: Western Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026
Figure 57: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026
Figure 58: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 59: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026
Figure 60: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026
Figure 61: Eastern Europe Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026
Figure 62: Eastern Europe Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026
Figure 63: Poland Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 64: Russia Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 65: Rest of Eastern Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 66: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026
Figure 67: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026
Figure 68: Eastern Europe Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026
Figure 69: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016 & 2026
Figure 70: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 71: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026
Figure 72: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026
Figure 73: APEJ Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026
Figure 74: APEJ Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026
Figure 75: China Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 76: India Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 77: ASEAN Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 78: Australia Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 79: Rest of APEJ Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 80: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026
Figure 81: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026
Figure 82: APEJ Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026
Figure 83: Japan Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026
Figure 84: Japan Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026
Figure 85: Japan Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026
Figure 86: Japan Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026
Figure 87: Japan Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026
Figure 88: Japan Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026
Figure 89: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By Country, 2016, 2026
Figure 90: MEA Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Country, 2015–2026
Figure 91: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By Immunohistochemistry (IHC) Test, 2016 & 2026
Figure 92: Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By Immunohistochemistry (IHC) Test, 2016–2026
Figure 93: MEA Cancer Tissue Diagnostics Market Share Analysis (%) By In situ Hybridization (ISH) Test, 2016 & 2026
Figure 94: MEA Cancer Tissue Diagnostics Market Y-o-Y Growth (%) By In situ Hybridization (ISH) Test, 2016–2026
Figure 95: GCC Countries Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 96: South Africa Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 97: Rest of MEA Europe Cancer Tissue Diagnostics Market Absolute $ Opportunity (US$ Mn), 2015 – 2026
Figure 98: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By Test Type, 2016 – 2026
Figure 99: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By IHC Test, 2016 – 2026
Figure 100: MEA Cancer Tissue Diagnostics Market Attractiveness Analysis By ISH Test, 2016 – 2026
Need more information about this report ?
Key Benefits
DIRECT ACCESS TO ANALYST
Get you queries resolved from our expert analysts before and after purchasing the report
CUSTOMIZE AS PER RESEARCH REQUIREMENT
Our expert team will assist and customize the report so that it best fit your exact requirement
INIMITABLE EXPERTISE ABOUT NICHE & EMERGING MARKETS
In-depth knowledge about emerging technologies across markets
ASSURED QUALITY
Enhanced focus on the quality and accuracy of the report
Call us on : + 44 (0) 20 7692 8790
OR
Select license type
Individual Price : $ 5000.00 Corporate Price : $ 7500.00 Enterprise Price : $ 10,000.00
Related Reports
Surgical Stapling Devices Market: APEJ, Western Europe, & North America in a Cutthroat Competition to Record the Highest CAGR Throughout the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016-2026
Muscle Stimulation Devices Market: Increasing Consumer Inclination towards Fitness & Sports, Coupled with High adoption in Physiotherapy Clinics & Home Care Settings to Boost Demand: Global Industry Analysis and Opportunity Assessment, 2016 - 2026
Endovenous Laser Therapy Market: Increasing Adoption of Endovenous Laser Therapy for Varicose Veins Treatment Likely to Fuel Market Revenue Growth: Global Industry Analysis and Opportunity Assessment 2016-2026
Global Pharmacovigilance Market: Increased regulatory convergence and stringent reporting measures to define pharmacovigilance activities globally
Static Compression Therapy Market : High incidence of Diabetes and Venous Ulcer to drive the demand for Static Compression Therapy Products : India Industry Analysis and Opportunity Assessment, 2015 - 2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report